EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Anti-EGFR plus anti-PD1 in advanced and refractory cutaneous squamous cell carcinoma: a cohort study

Camille Guy, Candice Hober, Sophie Maiezza, Philipe Jamme, Eve Desmedt, Laurent Mortier iD, Marie Boileau iD

The Oncologist · 09.03.2026 · 31 (4)

DOI: 10.1093/oncolo/oyag080 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift The Oncologist, online erschienen am 14.03.2026. Verfasst von Camille Guy und 6 weiteren Autor:innen. Beteiligte Einrichtung: Univ. Lille, CHU Lille, Service de Dermatologie, Lille, F-59000, France. Hauptthemen laut MEDLINE: Cutaneous Squamous Cell Carcinoma, Programmed Cell Death 1 Receptor, Skin Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Advanced cutaneous squamous cell carcinoma (cSCC) is associated with a poor prognosis. Although anti-Programmed cell Death protein 1 (anti-PD1) immunotherapy has improved cSCC management, its efficacy remains limited in some patients. Second-line options, including anti–epidermal growth factor receptor (anti-EGFR) antibodies and chemotherapies, exhibit transient efficacy and often good tolerability. Given the lack of successive treatment lines, new strategies are emerging, such as the combination of anti-PD1 and anti-EGFR agents. Materials and Methods We conducted a retrospective, monocentric cohort study including patients treated in our oncodermatology department between 2013 and 2024 for advanced cSCC refractory to anti-PD1 monotherapy and who received a combination of anti-PD1 and anti-EGFR as second- or third-line therapy. The aim was to assess the efficacy and safety of this combination.

Results

Fourteen patients were included, predominantly male (12/14), with a median age of 63 years. Most tumors originated from head and neck primary sites (n = 8). Eleven patients had progressed after prior exposure to both anti-PD1 therapy and cetuximab combined with chemotherapy. Thirteen patients received cetuximab (500 mg/m2) combined with pembrolizumab every 3 weeks, and 1 received cetuximab with nivolumab. The overall response rate was 38.5%, including 15.5% complete and durable response after treatment discontinuation, observed at 9 and 16 months, and 23% partial responses. Responses occurred early, with subsequent deepening observed in 2 patients. Adverse events were mainly grade 1, and only 2 cases experienced grade 3 toxicity (acneiform rash).

Conclusion

In a heavily pretreated real-life population with advanced cSCC, the anti-PD1/anti-EGFR combination showed clinical activity with acceptable safety, supporting its role as later-line strategy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cutaneous Squamous Cell CarcinomaProgrammed Cell Death 1 ReceptorSkin NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Squamous CellHumansMaleFemaleMiddle AgedAgedErbB ReceptorsRetrospective StudiesAntibodies, Monoclonal, HumanizedAged, 80 and overCohort Studies

Stichwörter der Autor:innen

advanced cutaneous squamous cell carcinomaanti-EGFRanti-PD1

Substanzen

Programmed Cell Death 1 ReceptorErbB ReceptorsPDCD1 protein, humanEGFR protein, humanAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Univ. Lille, CHU Lille, Service de Dermatologie, Lille, F-59000, France.
  • Univ. Lille, Inserm, CHU Lille, U1189 - ONCO-THAI - Assisted Laser Therapy and Immunotherapy for Oncology, F-59000 Lille, France.

ORCID-Profile: Laurent Mortier, Marie Boileau

Zitieren

APA

Guy, C., Hober, C., Maiezza, S., Jamme, P., Desmedt, E., Mortier, L., & Boileau, M. (2026). Anti-EGFR plus anti-PD1 in advanced and refractory cutaneous squamous cell carcinoma: a cohort study. The Oncologist, 31(4). https://doi.org/10.1093/oncolo/oyag080

Vancouver

Guy C, Hober C, Maiezza S, Jamme P, Desmedt E, Mortier L, et al. Anti-EGFR plus anti-PD1 in advanced and refractory cutaneous squamous cell carcinoma: a cohort study. The Oncologist. 2026;31(4). doi:10.1093/oncolo/oyag080

BibTeX
@article{Guy2026,
  author = {Guy, Camille and Hober, Candice and Maiezza, Sophie and Jamme, Philipe and Desmedt, Eve and Mortier, Laurent and Boileau, Marie},
  title = {Anti-EGFR plus anti-PD1 in advanced and refractory cutaneous squamous cell carcinoma: a cohort study},
  journal = {The Oncologist},
  year = {2026},
  volume = {31},
  number = {4},
  doi = {10.1093/oncolo/oyag080}
}
Kostenlos starten →